Originally published in SeedStage Digest (Mar 2024)
For years, FemTech was seen as a niche — a term often dismissed as "women's health" rather than what it truly represents: a multibillion-dollar opportunity.
That perception is finally changing.
Recent months have seen increased funding momentum behind early-stage startups addressing fertility, menopause, endometriosis, and diagnostic equity. A new generation of founders — many with medical backgrounds and personal stakes in the problems they're solving — are leading the charge.
**Case in point:**
LenaTrack, a hormonal health tracking app designed for perimenopausal women, closed a $2.1M seed round in late 2023. “We’re not a wellness app,” says founder Dana Green. “We’re a clinical tool — just one that puts patients first.”
What’s changed? A few things:
- The data has caught up: investors can now see how massive the addressable market really is.
- LPs are pushing VCs to diversify portfolios and fund more female founders.
- FemTech tools are getting better: smarter UX, better science, and clear monetization paths.
But perhaps most important is the growing network of founders, doctors, and patients demanding better. “This isn’t just about funding startups,” said VC partner Riley Morrison at a recent healthtech event. “It’s about fixing a system that has ignored half the population.”
FemTech isn’t emerging — it’s arriving. And investors who continue to underestimate it may find themselves late to a space that's about to explode.
Thank goodness innovation is needed in that space
Yay